ATHENA-MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer

被引：0

作者：

Monk, Bradley J.

Parkinson, Christine

Lim, Myong Cheol

O'Malley, David M.

Oaknin, Ana

Wilson, Michelle K.

Coleman, Robert L.

Lorusso, Domenica

Oza, Amit M.

Ghamande, Sharad A.

Christopoulou, Athina

Prendergast, Emily

Demirkiran, Fuat

Littell, Ramey D.

Chudecka-Glaz, Anita M.

Morgan, Mark Aloysuis

Goble, Sandra M.

Hume, Stephanie

Fujiwara, Keiichi

Kristeleit, Rebecca

机构：

[1] Univ Arizona, Coll Med, Tucson, AZ 85721 USA

[2] Creighton Univ, Univ Sch Med, Phoenix, AZ USA

[3] Addenbrookes Hosp, Med Oncol, Cambridge, England

[4] Natl Canc Ctr Korea, Gynecol Oncol, Goyang Si, Gyeonggi Do, South Korea

[5] Ohio State Univ, Div Gynecol Oncol, James Canc Ctr, Columbus, OH 43210 USA

[6] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Gynaecol Canc Programme, Vail dHebron Barcelona Hosp Campus, Barcelona, Spain

[7] Auckland City Hosp, Dept Canc & Blood, Auckland, New Zealand

[8] US Oncol Res, The Woodlands, TX USA

[9] Fdn Univ Policlin A Gemelli IRCCS, MITO, Rome, Italy

[10] Fdn Univ Policlin A Gemelli IRCCS, Gynecol Oncol Unit, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Rome, Italy

[12] Princess Margaret Hosp Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[13] Augusta Univ, Dept Obstet & Gynecol, Augusta, GA USA

[14] St Andrews Gen Hosp Patras, Med Oncol Unit, Patras, Greece

[15] Minnesota Oncol, Gynecol Oncol, Minneapolis, MN USA

[16] Istanbul Univ, Fac Med, Dept Gynecol Oncol, Istanbul, Turkey

[17] Kaiser Permanente Northern Calif, Gynecol Canc Program, San Francisco, CA USA

[18] Independent Publ Clin Hosp 2 PUM, Dept Surg Gynecol & Gynecol Oncol Adults & Girls, Szczecin, Poland

[19] Univ Penn Hlth Syst, Div Gynecol Oncol, Philadelphia, PA USA

[20] Clovis Oncol Inc, Biostat, Boulder, CO USA

[21] Clovis Oncol Inc, Clin Dev, Boulder, CO USA

[22] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, Hidaka, Saitama, Japan

[23] Guys & St Thomas NHS Fdn Trust, Dept Oncol, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 17期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA5500

引用

页数：1

共 50 条

[31] ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).
Hardy-Bessard, Anne-Claire
Moore, Kathleen N.
Mirza, Mansoor Raza
Asselain, Bernard
Redondo, Andres
Pfisterer, Jacobus
Pignata, Sandro
Provencher, Diane M.
Cibula, David
Reyners, Anna K. L.
Bodnar, Lubomir
Glasspool, Rosalind
Papadimitriou, Christos
Eitan, Rami
Han, Sileny N.
Duska, Linda R.
Rimel, B. J.
Divya, Gupta
Chen, Jian
Pujade-Lauraine, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[32] Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial
Wu, Lingying
Li, Ning
Wang, Jing
Li, Qingshui
Wang, Danbo
Tang, Junying
Zhang, Cuiying
Zhang, Guonan
Hao, Min
Yao, Desheng
Duan, Wei
Gao, Qinglei
Wang, Li
Zhang, Youzhong
An, Ruifang
Yin, Rutie
Zhou, Qi
Yang, Hongying
Zhu, Jianqing
Jiang, Kui
Wu, Qiang
Zhao, Weidong
Huang, Yi
Xia, Bairong
Yang, Xinfeng
Li, Bo
GYNECOLOGIC ONCOLOGY, 2024, 190 : S74 - S75
[33] SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.
Vergote, Ignace
Perez-Fidalgo, Jose Alejandro
Hamilton, Erika P.
Van Gorp, Toon
Valabrega, Giorgio
Laenen, Annouschka
Oza, Amit M.
Levy, Tally
Cibula, David
Sehouli, Jalid
Guerra, Eva
Chon, Hye Sook
Bergamini, Alice
Romero, Ignacio
Michel, Dayana
Shah, Jatin J.
Monk, Bradley J.
Slomovitz, Brian M.
Mirza, Mansoor Raza
Makker, Vicky
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[34] A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy
Martin, A. Gonzalez
Rojas, L. A.
Braly, P. S.
Barter, J.
O'Malley, D. M.
Oza, A. M.
Haggerty, A. F.
Vulsteke, C.
Provencher, D. M.
Graybill, W.
Li, Y.
Malinowska, I. A.
Mirza, M. R.
Vergote, I.
Pothuri, B.
Monk, B. J.
ANNALS OF ONCOLOGY, 2017, 28
[35] ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).
Hardy-Bessard, Anne-Claire
Moore, Kathleen N.
Mirza, Mansoor Raza
Asselain, Bernard
Redondo, Andres
Pfisterer, Jacobus
Pignata, Sandro
Provencher, Diane M.
Cibula, David
Reyners, Anna K. L.
Bodnar, Lubomir
Glasspool, Rosalind Margaret
Papadimitriou, Christos A.
Eitan, Rami
Han, Sileny
Duska, Linda R.
Rimel, Bj
Hazard, Sebastien
Chen, Jian
Pujade-Lauraine, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[36] Primary results from ENGOT-Ov41/GEICO 69-O/ANITA, a double-blind placebo-controlled phase 3 trial evaluating atezolizumab combined with platinum-based chemotherapy and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval >6 months
Gonzalez-Martin, Antonio
Rubio-Perez, Maria Jesus
Heitz, Florian
Christensen, Rene Depont
Colombo, Nicoletta
Gorp, Toon Van
Oaknin, Ana
Leary, Alexandra
Gaba, Lydia
Lebreton, Coriolan
Miguel De Sande Gonzalez, Luis
Romeo, Margarita
Redondo, Andres
Barretina-Ginesta, Maria-Pilar
Perez-Fidalgo, Alejandro
Santaballa, Ana
Bermejo, Maria Jose
Bruchim, Ilan
Ray-Coquard, Isabelle
Selle, Frederic
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A35 - A36
[37] ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
Vergote, Ignace
Sehouli, Jalid
Salutari, Vanda
Zola, Paolo
Madry, Radoslaw
Wenham, Robert Michael
Korach, Jacob
Pautier, Patricia
Cibula, David
Lheureux, Stephanie
Hasegawa, Kosei
Kim, Byoung-Gie
Lai, Chyong-Huey
Gonzalez-Martin, Antonio
Liu, Qi
Keefe, Stephen Michael
Puglisi, Martina
Topuz, Samet
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[38] Chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase 3 trial
Mahner, S.
Lueck, H. -J.
Grischke, E. -M.
Rau, J.
Gropp-Meier, M.
Schmalfeldt, B.
Meier, W.
Hasenburg, A.
Belau, A.
Vergote, I.
Zorr, A.
Huels, R.
Gerber, B.
du Bois, A.
Marme, F.
Hilpert, F.
Canzler, U.
Kurzeder, C.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 97 - 97
[39] Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
Zhou, Caicun
Wang, Ziping
Sun, Yuping
Cao, Lejie
Ma, Zhiyong
Wu, Rong
Yu, Yan
Yao, Wenxiu
Chang, Jianhua
Chen, Jianhua
Zhuang, Wu
Cui, Jiuwei
Chen, Xueqin
Lu, You
Shen, Hong
Wang, Jingru
Li, Peiqi
Qin, Mengmeng
Lu, Dongmei
Yang, Jason
LANCET ONCOLOGY, 2022, 23 (02): : 220 - 233
[40] Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
Boyer, Michael
Hui, Rina
Urban, Damien
Clingan, Philip
Su, Wu-Chou
Devaux, Celine
Gadgeel, Shirish
Garassino, Marina
Leopold, Lance
Daniel, Jeannie
Munteanu, Mihaela C.
Samkari, Ayman
Luo, Yiwen
Abreu, Delvys Rodriguez
BMC CANCER, 2024, 23 (SUPPL 1)

← 1 2 3 4 5 →